Capstan Therapeutics
Vision
We transform medicine by in vivo precision engineering of cells.
Approach
Capstan Therapeutics is advancing precision in vivo engineering in a scalable and controlled format to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need. The core technology comprises targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body. The company is combining the power of cell therapy with the precision of genetic medicines to deliver breakthrough medicines to patients for oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders.
Capstan Therapeutics is addressing
CEO:
Laura Shawver, Ph.D., - President and CEO
Founding CEO:
Christian Homsy, M.D., MBA
First investment:
June 2022